Sunesis Pharmaceuticals, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Daniel C Adelman

Jeffrey A Silverman

Anantha R Sudhakar

Jeffrey William Jacobs

Marc Evanchik

Michelle Arkin

Duncan Walker

Satoshi Nakao

Jasmin Wright

Jennifer Hyde

Masaru Higaki

Caroline Darne Scatena

Michael Arkin

Glenn Michelson

Higaki Masaru

Jasmine Wright

Nakao Satoshi

The present invention relates to SNS-595 and methods of treating cancer using the same.

SNS-595 and methods of using the same

Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions.

Compounds and compositions for treatment of cancer

1,8-naphthyridine compounds for the treatment of cancer

Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.

Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Methods of using SNS-595

Growing community of inventors

Redwood City, CA, United States of America

Daniel C Adelman